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ABSTRACT 
Objective: The present work was to formulate buoyant system in order to protect the drug from gastric acid degradation, increasing the gastric 
residence time, control the drug leaching by use of enteric polymers, prolong the half life for longer duration of action, furthermore to prevent 
dosage form adherence to the mucous wall in order to avoid incomplete drug release. Moreover the side effects of effervescent dosage form could be 
well controlled.  
Methods: Employed was emulsion solvent diffusion, using 23factorial design with Eudragit®L100 and RS100 in solvent mixture dichloromethane 
and ethanol whereas the optimization and validation were carried out through Design-Expert 9.0.3 software. 
Result: Optimized formulation (LRS-O) showed buoyancy (B %) of 78.88±0.23 %, entrapment efficiency (EE %) of 71.12±0.04 % and drug release 
over 12 h (CDR12 h %) of 99.50±0.08 % in PB pH 6.8. Whereas in PB pH 7.4 the actual values for B %, EE % and CDR12 h % was 87.35±0.68 %, 
89.30±0.05 % and 98.68±0.37 %. Smaller error values for both showed that actual responses were within the predicted range. Particles were in the 
size range 80-100 µm with spherical, rough, porous and internal hollow cavity. Drug-polymer interactions were negligible and showed zero order 
patterns over 12 hrs.  
Conclusion: Enhanced bioavailability of the drug was achieved with excellent responses of B %, EE % and CDR12 h % and the software used for the 
optimization and validation of formulation design, was economical and reduces the number of trials. 
Keywords: Emulsion solvent diffusion method, Gastro retentive drug delivery, Non effervescent, Pantoprazole sodium, 23 factorial design. 
 
INTRODUCTION 
Intestinal absorption occurs through passive transport and follows Fickʼs 
law of diffusion from higher concentration in the gastrointestinal tract 
(GIT) to the lower one in systemic circulation. Diffusion through 
intestinal cells depends on drug ionization, solubility, concentration and 
permeability. Drug diffuses in its molecular form from the lipophilic 
mucosal wall of intestinal membranes in to the systemic circulation 
because of the larger partition coefficient between membranes and 
gastrointestinal fluids. For absorption to occur both drug solubility and 
permeability play a vital role in its transport from intestinal mucosa and 
in to the systemic circulation [1]. 
Different types of response surface methodology (RSM) designs 
include 3-level factorial design, central composite design (CCD), box-
Behnken design and D-optimal design. RSM is used when only a few 
significant factors are involved in optimization. It is a computer 
based optimization technique utilizing a polynomial equation [2-4].  
The gastric retention time (GRT) of the dosage form could be 
increased by providing buoyancy has been reported. Buoyancy could 
be achieved by effervescent as well as non-effervescent techniques. 
They provide better drug absorption at the proximal small intestine 
as well as in the stomach [5]. Effervescent technique has been 
reported with the side effects of violent gas generation; 
disintegration of the dosage form; burst release; dose dumping and 
alkaline microenvironment, these drawbacks could be well 
controlled by non-effervescent technique [6]. 
The single unit product has the disadvantages of uneven distribution 
in the gastrointestinal tract and may also cause local damage by dose 
dumping effect [7]. The use of oral conventional dosage form was 
limited due to their inability to increase their residence time in the 
stomach and proximal portion of the small intestine [8]. In contrast 
the multiple unit products like microballoons are less affected by the 
pH and the gastric transit time, attain more constant plasma levels, 
give higher accuracy in reproducibility and achieve a sustain-release 
effect [9]. 
Pantoprazole sodium (PAN) is a proton pump inhibitor [10] and 
belongs to biopharmaceutical classification system (BCS) class I with 
high solubility and permeability, degrades in the acidic environment 
hence for restoring its efficacy it is available for administration as 
lyophilized powder and as enteric coated gastric resistant tablets 
[11]. It is administered to treat gastric ulcers, gastro-esophageal 
reflux disease and to treat infections caused due to Helicobacter 
pylori [12]. It is chemically, sodium 5-(difluoromethoxy)-2-{[(3, 4-
dimethoxy 2-pyridinyl) methyl] sulfinyl}-1H-benzimidazole. It 
consists of two heterocyclic moieties-a pyridine and a benzimidazole 
moiety-linked via methyl sulfinyl group, inhibits the gastric H+/K+-
ATPase via covalent binding to cysteine residue of the proton pump 
[13]. PAN degrades faster at low pH due to its shorter elimination 
half life of 1 h and bioavailability of 77 %, so it requires 
encapsulation with enteric polymers has been reported to enhance 
its duration of action in case of oral dosage forms.  
The glass transition temperature of Eudragit®RS100 could be lowered 
by adding small amount of dibutyl phthalate (DBT) (10-25 %) that fits 
between the glassy molecules, gives them mobility and thus increases 
its solubility whereas Eudragit®E100 do not require the addition of 
plasticizer for solubilization [14]. Magnesium stearate in 
concentration 0.25 to 5 % w/w is of low bulk density and hydrophobic 
in nature. Polyvinyl alcohol (PVA) (0.75 % w/v) was used as a 
dispersing agent, sodium citrate (0.3-2.0 %) as a buffering agent for 
the medium. Sodium chloride serves as channeling agent. When the 
coated particles come in contact with aqueous medium, sodium 
chloride may leach out creating channels within the film coat [15].  
In previous reported works, it has been successfully encapsulated 
with Eudragit®S grades by emulsion solvent evaporation and spray 
drying methods, for its protection in the gastric mucosa [16, 17]. Our 
aim in the present work was to give porous nature as well as 
sustained release characteristics to the formulation, which could be 
achieved by Eudragit®L100 and RS100 combinations. Due to the 
presence of ammonium group Eudragit®RS100 provides porosity to 
the formulation and also shows pH independent dissolution. The 
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encapsulation was achieved through enteric coating polymer 
Eudragit®L100 that dissolves above pH 6 in the jejunum. 
In order to achieve the objectives of buoyancy, controlling the rate 
of drug release, increase in the GRT and controlling the 
fluctuations of drug level in plasma, we formulated hollow 
microspheres (microballoons) by emulsion solvent diffusion 
method [18], employing non-effervescent technique with 23 
factorial designs. These systems may also be advantageous for 
drugs that have narrow absorption window, irritant to gastric 
mucosa and with stability problems. The microballoons formed 
were evaluated for its percentage swelling, in vitro buoyancy and 
entrapment efficiency. They are characterized by particle size 
analysis, SEM, FTIR, in vitro release, mechanism of release and for 
stability studies. Stability testing of optimized formulation 
provides the evidence on how the quality shows variations with 
time, predicts the shelf life and suggests the optimal storage 
conditions [19]. 
MATERIALS AND METHODS 
Materials 
Pantoprazole sodium (PAN) was obtained as a gift sample from 
Akum Drugs (Haridwar, India); Eudragit®L100 and RS100 from 
Evonic industries (Mumbai, India). Magnesium stearate, 
dichloromethane, DBT and PVA were purchased from LOBA 
Chemicals (Mumbai, India). All other chemicals used were of 
analytical grades. Differential UV-spectrophotometric studies were 
carried out using double-beam UV-spectrophotometer-2203, 
Systronics Pvt. Ltd. (Ahmedabad, Gujarat, India). 
Methods 
Preparation of PAN-loaded microballoons 
Microballoons were prepared by emulsion solvent diffusion method 
[20]. In this method Eudragit®L100 (600-900 mg) and RS100 (600-900 
mg) were dissolved in ethanol-dichloromethane mixture each 8 ml. PAN 
(40 mg) was mixed with sodium chloride (0.09 g) separately with the 
help of mechanical stirrer which serves as channeling agent. This drug 
mixture was added to above prepared polymer solution with continuous 
stirring at 300 rpm, than DBT (20 % w/v) was incorporated and stirred 
for 1 h. This drug-polymer mixture was slowly introduced into aqueous 
solution of PVA (0.75 % w/v in 200 ml distilled water) containing 
sodium citrate (1 % w/v) as buffering agent to get the desired pH of the 
medium. The solution was maintained at 40 °C on a magnetic stirrer at 
300 rpm for 1 h and the prepared microballoons were collected by 
filtration, washed three times with distilled water, dried at room 
temperature and kept in desiccators. 
Experimental design 
A 23 Full Factorial Designs (FFD) was used for the optimization of 
sustained release PAN formulations. Magnesium stearate (X1 % 
w/w), Eudragit®L100 (X2, mg) and Eudragit®RS100 (X3, mg) were 
the three factors (independent variables) studied. The responses 
(dependent variables) studied were buoyancy (Y1, %), drug 
entrapment efficiency (Y2, %) and amount of drug released in 12 h 
(Y3, %) in both phosphate buffer (PB) pH 6.8 and 7.4. The 
experimental design was evaluated using Design-Expert 9.0.3 
software (Stat-Ease Inc., USA) and the effect of three factors, two 
factor levels and their interaction on three basic responses was 
investigated and evaluated for all batches LRS 1-8 (table 1).
  
Table 1:23 full factorial design layouts for different formulations in PB pH 6.8 and 7.4 
Code Independent variables (factors, X) pH Dependent variables (responses, Y) 
Magnesium stearate  
(X1, % w/w) 
Eudragit® L100  
(X2, mg) 
Eudragit®RS 100 (X3, mg) 
 
B % a, e EE % b, e CDR12 h % c, e 
LRS-1 2.5 (-1) 600(-1) 600(-1) 6.8 28.97±0.021 10.88±0.045 75.05±0.017 
7.4 33.82±0.032 46.39±0.008 74.64±0.028 
LRS-2 5.0 (+1) 600(-1) 600(-1) 6.8 78.88±0.043 71.12±0.008 99.50±0.015 
7.4 87.35±0.012 89.30±0.043 98.68±0.073 
LRS-3 2.5 (-1) 900(+1) 600(-1) 6.8 41.03±0.024 26.67±0.021 95.92±0.026 
7.4 49.35±0.067 61.86±0.084 94.37±0.031 
LRS-4 5.0 (+1) 900(+1) 600(-1) 6.8 75.59±0.011 77.09±0.012 71.55±0.018 
7.4 81.42±0.078 66.76±0.006 63.18±0.046 
LRS-5 2.5 (-1) 600(-1) 900(+1) 6.8 Cd Cd Cd 
7.4 Cd Cd Cd 
LRS-6 5.0 (+1) 600(-1) 900(+1) 6.8 46.87±0.025 40.71±0.046 66.54±0.072 
7.4 51.82±0.098 59.29±0.061 72.75±0.079 
LRS-7 2.5 (-1) 900(+1) 900(+1) 6.8 61.05±0.034 30.86±0.063 64.08±0.084 
7.4 67.92±0.033 55.39±0.068 69.09±0.062 
LRS-8 5.0 (+1) 900(+1) 900(+1) 6.8 88.46±0.009 62.13±0.031 77.01±0.064 
7.4 93.37±0.065 73.75±0.041 84.21±0.067 
(+1) = higher values; (-1) = lower values; a B % = percentage buoyancy; bEE % = percentage entrapment efficiency; cCDR12 h % = cumulative 
percentage drug release over 12 h; dCd = collapsed; emean±S. D.: n = 3. 
 
Evaluation of microballoons  
Percentage swelling (Ps) 
The swelling kinetics of microballoons was carried out by the 
gravimetric method in triplicate. For the study 50 mg of microballoons 
were immersed in PB pH 6.8 and 7.4 (100 ml, 37±0.5 °C) in a beaker, 
maintained at 100 rpm on a magnetic stirrer.  
After fixed intervals of 1 h they were removed and weighed 
immediately. The difference in weights gave the amount of water 
uptake by the microballoons. Ps was calculated by following equation 




�× 100 (1)  
Where, Ws is weight of swollen and Wd is the weight of the dried 
microballoons.  
Percentage in vitro buoyancy (B %) 
The study was carried out by spreading 50 mg of dried 
microballoons over the surface of PB pH 6.8 and 7.4 (100 ml, 37±0.5 
°C) containing 0.02 % w/v Tween 80 in the dissolution apparatus 
(type II) and stirred at 100 rpm on a magnetic stirrer for 12 h. After 12 
h the microballoons were collected, dried, weighed and then kept in 
desiccators until constant weight was achieved. Percentage buoyancy 




�× 100 (2) 
Where, WF is weight of floated and WNF is the weight of the non-
floated microballoons. 
Percentage entrapment efficiency (EE %) 
For the study dried microballoons equivalent to 40 mg of PAN was 
crushed and dissolved in 100 ml of PB pH 6.8 and 7.4. The contents 
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were shaken on vortex mixture for 1 h to extract the drug and then 
filtered through whatman filter paper 1. The drug concentration was 
determined spectrophotometrically at λmax 215 nm and 288 nm in 
triplicate. The percentage drug entrapped was calculated by 
following equation [23]:  
EE % =
Calculated drug content (x)
Theoretical drug content
 × 100 (3) 
Optimization and validation of experimental design 
On the basis of evaluation results of the response parameters the 
formulation with maximum B %, EE % and highest CDR 12 h % over 
12 h was selected. For validating the design polynomial equations 
were generated for each response using the software. The statistical 
model equation consisting of interactive as well as polynomial terms 
for each response parameters for the evaluation:  
[y = b0 + b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3 +
b123X1X2X3 (4) 
 
Where b0, the intercept is the arithmetic mean was found out with 
the help of table 1. The main effects (regression coefficients) b1, b2, 
b3, b12, b13, b23 and b123 were calculated by use of signs in the columns, 
by adding or subtracting the value of the obtained responses, Y. 
Finally the values are summed up and divided with the number of 
formulations [24].  
Model matrix method was used for the optimization process. The 
interaction effects were calculated in the same way as that of the 
main effects. The signs of the interaction effects such as: X1X2, X1X3, 
X2X3 and X1X2X3 were calculating by multiplying the signs of the 
corresponding main effects and separate columns are constructed 
for each effect. To validate the polynomial equation model, one 
check point formulation LRS-O was also formulated and evaluated in 
both the mediums, the significance of model design and individual 
response parameters (p<0.05) was estimated by one-way ANOVA 
method. The percentage error was calculated with the help of 
following equation: 
 
 Percentage error (%) = (predicted value−experimental value)
predicted value
× 100 (5) 
 
Characterization of optimized microballoons 
Determination of particle size  
Particle size analysis of the optimized formulation was carried out 
by optical microscopy method. For the study sizes of 200 particles 
was determined by calibrating the eyepiece micrometer with the 
help of stage micrometer. The particles are arranged on the basis of 
size ranges. The number of particles in each size range are then 
counted and tabulated. Percentage in each range was calculated 
using following equation:  
% in each range =
Number of particles
200
× 100 (6) 
Scanning electron microscopy (SEM) 
The external and internal morphology of the optimized formulation 
was analyzed by SEM (JEOL 5400, Kyoto, Japan). For the study 
sample was prepared by mounting it over the metal grid with the 
help of adhesive tape, the grid was than coated with gold ion and 
visualized under 1x, 150 x and 500 x magnifications. 
Fourier transform infrared spectroscopy (FTIR) 
The study was performed (IR-Thermo Nicklet 380 US) for the 
identification of specific functional groups within the samples of: 
PAN, Eudragit®L100, Eudragit®RS100 and optimized formulation. 
For the analysis about 3-5 mg of sample was ground in pestle and 
mortar with 100 mg KBr and transformed in to transparent discs 
with the help of pellet press then spectra were obtained in the 
range 4000-500 cm-1. Resulting spectra’s between transmittance 
and wave number (cm-1) were used to identify drug-polymer 
interactions. 
In vitro release studies 
The study was carried out at 37 °C in PB pH 6.8 and 7.4 which were 
prepared by taking 50 ml of 0.2M KH2PO4 and 39.1 ml of 0.2 N NaOH 
in volumetric flask to make volume 200 ml with distilled water. 0.2 
M KH2PO4 was prepared by dissolving 27.218 g of KH2PO4 in distilled 
water to make volume 1000 ml. Each batch of microballoons 
equivalent to 40 mg of PAN was added to 250 ml of both mediums in 
an iodine flask and shaken for 1 h at 50 rpm maintained at 37 °C. 
The samples were withdrawn at regular intervals of 1 h up to 12 hrs. 
Each withdrawn sample was immediately replaced with the fresh 
sample to maintain the sink conditions. Sample was then analyzed at 
λ max 215 nm and 288 nm in triplicate using UV-spectrophotometer 
[25]. For confirming the accuracy, the release profiles of check point 
formulation LRS-O was compared with the marketed formulation 
Pantop-40 (Aristo pharmaceutical Pvt. Ltd. Mumbai, India).  
Drug release kinetics and mechanism 
To predict and correlate the release kinetics of PAN loaded 
microballoons in PB pH 6.8 and 7.4, the obtained data were fitted in 
to a suitable mathematical models. In zero-order, first-order, 
Higuchi and Korsmeyer-peppas model plot were made between T Vs 
% CDR, T Vs log % CDR, √T Vs % CDR and log T Vs log % CDR. In 
Korsmeyer-peppas model the competing release mechanism of the 
formulations was distinguished as Fickian release (diffusion-
controlled with ⃰ n ≤ 0.43), Non-Fickian release (anomalous 
transport; 0.43 ≤ n ≤ 0.85) and case-II transport (relaxation-
controlled; *n ≥ 0.85) [26-28].  
Stability study 
Microballoons after packing in market capsule kept in vials at 40±2 
°C/75±5 % RH for a period of six months and sampled each month 
for physical changes, % buoyancy and % entrapment efficiency and 
the data obtained was tabulated for both PB pH 6.8 & 7.4. The 
stability protocol was in compliance with that of the world health 
organization (WHO) guidelines. One-way analysis of variance 
(ANOVA) F-test was applied for checking the statistical significance 
(*p>0.05).  
RESULTS  
The optimal preparative conditions found out were stirring speed of 
300 rpm, temperature of 40 °C and the stirring time of 1 h. It was 
cleared from the results of B %, EE % and CDR12 h % that the 
optimum concentrations for independent variables was 5 % w/w of 
Magnesium stearate, 600 mg of Eudragit®L100 and 600 mg of 
Eudragit®RS100 in order to get the desired responses.  
In the experimental designs a total of eight formulations (LRS 1-8) 
were made. In LRS-2 the percentage swelling in PB pH 6.8 and 7.4 
was found to be 0.011-0.045 g/g and 0.016-0.048 g/g for 10 h study. 
The percentage buoyancy in PB pH 6.8 and 7.4 was between 28.97-
88.46 % and 33.82-93.37 % and the percentage entrapment was 
found out to be 10.88-77.09 % in PB pH 6.8 and 46.39-89.3 % in PB 
pH 7.4.  
The formulation with higher responses for percentage swelling, 
buoyancy and entrapment efficiency was selected as the best. 
Formulation LRS-2 gave best results for percentage swelling, 
buoyancy and entrapment efficiency in both PB pH 6.8 and 7.4 which 
was found to be 0.045 g/g and 0.048 g/g, 78.88±0.043 % and 
87.35±0.012 %, 71.12±0.008 % and 89.30±0.043 %. More over the 
CDR12 h % was found as 99.50±0.015 % for PB pH 6.8 and 
98.68±0.073 % for PB pH 7.4 as shown in table1. 
Optimization 
For the optimization suitable polynomial equations were generated 
with the help of Design-Expert 9.0.3 software for all the three 
dependent variables such as B %, EE % and CDR12 h % for both PB 
pH 6.8 and 7.4. The equations were analyzed with statistical 
parameters such as multiple correlation coefficients (R2) and the 
predicted residual sum of squares (PRESS) as presented in table 2. 
The value of PRESS serves as the measure of fitness of the model 
with the data points. The ANOVA results showed that the PRESS 
values were smaller for all the models and thus the data points were 
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better fitted with the model and all the response models were 
significant with the response parameters. 
Process optimization in PB pH 6.8 
B% = 60.12 + 22.67X1 + 15.91X2 − 4.01X3 − 4.97X1X2 − 1.45X1X3
+ 13.41X2X3 −  0.58X1X2X3 (7) 
[R2 = 0.9970; F value = 478.82; ⃰ p < 0.05] 
EE% = 45.63 + 26.09X1 + 10.57X2 − 7.43X3 − 2.75X1X2 − 5.52X1X3
+ 4.36X2X3 + 0.05X1X2X3 (8) 
[R2 = 0.9989; F value = 51186; ⃰ p < 0.05] 
CDR12h% = 78.52 + 11.36X1 + 9.63X2 − 19.19X3 − 14.63X1X2
+ 11.34X1X3 + 11.66X2X3 (9) 
[R2 = 0.9990; F value = 380.63; ⃰ p < 0.05] 
From the ANOVA results for B %, EE % and CDR12 h % as the 
dependent responses, the model equation for B % showed that 
coefficients b3, b12 and b13 had no static significance (*p>0.05) 
with the model F-value of 380.63 and R2 value of 0.9970, the 
model equation for EE % had all coefficients significant 
(*p<0.05) with model F-value of 51186 and R2 value of 0.9989, 
whereas for the model equation for CDR12 h% (PB pH 6.8) it 
was evident that all the coefficients had static significance 
(*p<0.05) with the model F-value of 380.63 and R2value of 
0.9990 (table 2). 
For model simplification the non-significant terms ⃰ p>0.05 were 
eliminating from all the polynomial equations obtained from the 
multiple regression analysis, so the final equation becomes:  
B% (Y1) = 60.12 + 22.67X1 + 15.91X2 + 13.41X2X3
− 0.58X1X2X3 (10) 
EE% (Y2) = 45.63 + 26.09X1 + 10.57X2 − 7.43X3 − 2.75X1X2
− 5.52X1X3 + 4.36X2X3 + 0.05X1X2X3 (11) 
CDR12 h% (Y3) = 78.52 + 11.36X1 + 9.63X2 − 19.19X3 − 14.63X1X2
+ 11.34X1X3 + 11.66X2X3 (12)
 
Table 2: ANOVA summary for response parameters in PB pH 6.8 and 7.4 
Source Sum of squares d. f. a Mean square F-value P-value (Prob>F) 
pH 6.8 7.4  6.8 7.4 6.8 7.4 6.8 7.4 
(a) B % b          
Model 6066.24 6817.90 6 1011.04 1136.32 478.82 377.07 0.0350 (S) 0.0394 (S) 
X1 3150.20 3315.83 1 3150.20 3315.83 1491.91 1100.32 0.0165 (S) 0.0192 (S) 
X2 1551.52 1772.21 1 1551.52 1772.21 734.79 588.09 0.0235 (S) 0.0262 (S) 
X3 98.63 188.47 1 98.63 188.47 46.71 62.54 0.0925 (NS) 0.0801 (NS) 
X1X2 151.47 285.96 1 151.47 285.96 71.73 94.89 0.0748 (NS) 0.0651 (NS) 
X1X3 12.98 8.67 1 12.98 8.67 6.15 2.88 0.2441 (NS) 0.3391 (NS) 
X2X3 1101.45 1246.75 1 1101.45 1246.75 521.64 413.72 0.0279 (S) 0.0313 (S) 
(b) EE % c          
Model 5543.51 4809.74 6 923.92 801.62 51186.63 752.13 0.0034 (S) 0.0279 (S) 
X1 4169.67 1967.53 1 4169.67 1967.53 2.310E+005 1846.06 0.0013 (S) 0.0148 (S) 
X2 685.24 492.67 1 685.24 492.67 37963.45 462.25 0.0033 (S) 0.0296 (S) 
X3 338.78 719.72 1 338.78 719.72 18769.00 675.29 0.0046 (S) 0.0245 (S) 
X1X2 46.37 778.94 1 46.37 778.94 2568.89 730.85 0.0126 (S) 0.0235 (S) 
X1X3 187.02 111.30 1 187.02 111.30 10361.10 104.43 0.0063 (S) 0.0621 (NS) 
X2X3 116.43 739.59 1 116.43 739.59 6450.63 693.93 0.0079 (S) 0.0242 (S) 
(c) CDR12 h% d          
Model 6549.90 6592.89 6 1091.65 1098.82 380.63 1526.13 0.0392 (S) 0.0196 (S) 
X1 791.03 814.46 1 791.03 814.46 275.81 1131.20 0.0383 (S) 0.0189 (S) 
X2 569.03 524.56 1 569.03 524.56 198.40 728.55 0.0451 (S) 0.0236 (S) 
X3 2257.58 1373.40 1 2257.58 1373.40 787.16 1907.51 0.0227 (S) 0.0146 (S) 
X1X2 1311.49 1592.17 1 1311.49 1592.17 457.28 2211.35 0.0297 (S) 0.0135 (S) 
X1X3 787.85 1128.60 1 787.85 1128.60 274.70 1567.50 0.0384 (S) 0.0161 (S) 
X2X3 832.93 1159.69 1 832.93 1159.69 290.42 1610.68 0.0373 (S) 0.0159 (S) 
X1, X2 and X3 represents amount of Magnesium stearate (% w/w), Eudragit® L 100 (mg) and Eudragit® RS 100 (mg) respectively. X1X2, X1X3 and X2X3 
are the interaction effects; S and NS indicate significant and not significant respectively. 
ad. f. indicate degree of freedom, bB % = percentage buoyancy, cEE % = percentage entrapment efficiency, dCDR12 h % = cumulative percentage drug 
release over 12 h. 
 
Process optimization in PB pH 7.4 
B% = 66.43 + 23.26X1 + 17.01X2 − 5.54X3 − 6.83X1X2 − 1.19X1X3
+ 14.26X2X3 −  0.70X1X2X3 (13) 
[R2 = 0.9986; F value = 377.07; ⃰ p < 0.05] 
EE% = 64.67 + 17.92X1 + 8.96X2 − 10.84X3 − 11.27X1X2+4.26X1X3
+ 10.98X2X3 − 0.41X1X2X3 (14) 
[R2 = 0.9988; F value = 752.13; ⃰ p < 0.05] 
CDR12 h% = 79.56 + 11.53𝑋𝑋1 + 14.97𝑋𝑋2 − 14.97𝑋𝑋3
− 16.12𝑋𝑋1𝑋𝑋2+13.57𝑋𝑋1𝑋𝑋3 + 13.76𝑋𝑋2𝑋𝑋3
−  0.34𝑋𝑋1𝑋𝑋2𝑋𝑋3 (15) 
[R2 = 0.9996; F value = 1526.13; ⃰ p < 0.05] 
The results obtained from ANOVA analysis showed that in the model 
equations for B % the coefficients b3, b12 and b13 had no static 
significance (* p>0.05) with F-value of 377.07 and R2 value of 
0.9986, the polynomial equation for the response EE % showed only 
one coefficient b13 that has no static significance (*p>0.05) with the 
model F-value of 752.13 and R2 of 0.9988, while evaluating the 
polynomial equation for the response CDR12 h %, all coefficients 
were statistically significant (*p<0.05) with F-value of 1526.13 and 
R2 value of 0.9996 (table 2). 
After eliminating the non-significant terms (* p>0.05) the final 
model equation becomes:  
B% (Y1) = 66.43 + 23.26X1 + 17.01X2 + 14.26X2X3
− 0.70X1X2X3 (16) 
EE% (Y2) = 64.67 + 17.92X1 + 8.96X2 − 10.84X3
− 11.27X1X2+4.26X1X3 + 10.98X2X3
−  0.41X1X2X3 (17) 
CDR12 h % (𝑌𝑌3) = 79.56 + 11.53𝑋𝑋1 + 14.97𝑋𝑋2 − 14.97𝑋𝑋3
− 16.12𝑋𝑋1𝑋𝑋2+13.57𝑋𝑋1𝑋𝑋3 + 13.76𝑋𝑋2𝑋𝑋3
− 0.34𝑋𝑋1𝑋𝑋2𝑋𝑋3 (18) 
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The results of investigated responses such as B %, EE % and CDR12 
h % for all batches of formulations (LRS 1-8) for both the mediums 
PB pH 6.8 and 7.4 was found within the limits. Linear correlation 
plots between the actual and the predicted responses are depicted in 
Figure1 (PB pH 6.8) and fig. 2 (PB pH 7.4). Further we have 
elucidated the main and the interaction effects of independent 
variables over the responses through response surface method 
using Design-Expert 9.0.3 software, as it is considered as the best for 
the development and optimization of formulations.  
In PB pH 6.8 the response surface plots for B % showed an increase 
in response with increase of both Magnesium stearate (X1) and 
Eudragit® L100 (X2), the response surface plots related to EE % 
predicts an increase of response with an increase of both 
Magnesium stearate (X1) and Eudragit® L100 (X2) and decrease of 
Eudragit® RS 100 (X3), whereas the plot for CDR12 h % showed an 
increase with increasing Magnesium stearate (X1) and Eudragit® 
L100 (X2) and decreasing Eudragit® RS100 (X3) fig. 3(a-c). On the 
other hand the response surface plots obtained in case of PB pH 7.4 
depicts increase of B % with increasing Magnesium stearate (X1) and 
Eudragit® L100 (X2) whereas increase in EE % as well as CDR12 h % 
was due to increase of both Magnesium stearate (X1) and Eudragit® 
L100 (X2) and decrease of Eudragit® RS 100 (X3) fig. 4 (a-c). 
Optimized formulation with the desired response was obtained by 
numerical optimization technique using the desirability approach. 
The desirable values of independent variables (factors) in PB pH 
6.8 were: X1 = 5.00 %, X2 = 601.01 mg and X3 = 600.00 mg, whereas 
the desirable ranges of dependent responses were restricted to 75 
≤ B % ≤ 80 , 70 ≤ EE % ≤ 75 and 95 ≤ CDR12 h % ≤ 100. The 
obtained predicted values for dependent variables were B % = 
79.37, EE % = 71.09 and CDR 12 h % = 99.99. In PB pH 7.4 the 
desirable values of independent variables are: X1 = 5.00 %, X2 = 
600.00 mg and X3 = 600.00 mg while the desirable ranges of 
dependent responses were restricted to: 85 ≤ B % ≤ 90, 85 ≤ EE % 
≤ 90 and 95 ≤ CDR12 h % ≤ 100. The predicted values for the 




Fig. 1: Residual plot showing scatter of residuals versus predicted values (a), and linear correlation plot between the actual and predicted 
values (b) in phosphate buffer pH 6.8 for B, EE and CDR12 h % 
 
Table 3: Confirmation of optimization capability 

















5.00 601.01 600.00 Ba 79.37 78.88±0.23 0.617 
    EEb 71.09 71.12±0.04 -0.042 
    CDR12hc 99.99 99.50±0.08 0.490 
LRS-O 
(pH 7.4) 
5.00 600.00 600.00 Ba 87.96 87.35±0.68 0.693 
    EEb 89.66 89.30±0.05 0.363 
    CDR12hc 98.98 98.68±0.37 0.303 
aB = buoyancy; bEE = entrapment efficiency; cCDR12 h = cumulative drug release over 12 h; dPercentage error (%) = (predicted value   ̶experimental 
value)/predicted value x 100. 
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Fig. 2: Residual plot showing scatter of residuals versus predicted values (a), and linear correlation plot between the actual and predicted 
values (b) in phosphate buffer pH 7.4 for B, EE and CDR12 h % 
 
 
Fig. 3:(a-c) Response surface plot predicting mutual effects of amount of Magnesium stearate (% w/w), Eudragit®L100 (mg) and 
Eudragit®RS100 (mg) on B, EE and CDR12 h % in phosphate buffer pH 6.8 
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Fig. 4:(a-c) Response surface plot predicting mutual effects of amount of Magnesium stearate (% w/w), Eudragit®L100 (mg) and 
Eudragit®RS100 (mg) on B, EE and CDR12 h % in phosphate buffer pH 7.4 
 
Validation of factorial design 
Further for validating the optimization capability an extra check point 
formulation LRS-O was formulated using the optimal process variables 
and evaluated for B %, EE % and CDR12 h % for both the mediums. 
The experimental and the predicted responses by the mathematical 
model were presented in table 3 and the percentage error was 
calculated. Optimized formulation (LRS-O) showed buoyancy of 
78.88±0.23 %, entrapment efficiency of 71.12±0.04 % and drug 
release in 12 h of 99.50±0.08 % in PB pH 6.8 with smaller error values 
(0.617, -0.042 and 0.490). Whereas in PB pH 7.4 the actual values for B 
%, EE % and CDR12 h % was 87.35±0.68 %, 89.30±0.05 % and 
98.68±0.37 % with smaller error values (0.693, 0.363 and 0.303) 
respectively. Hence this validation approach confirms that the 
mathematical models obtained from 23 FFD were well fitted. 
Characterization of optimized microballoons  
Particle size analysis 
The sizes of dried PAN-loaded microballoons for all LRS formulations 
(LRS 1-8) were measured by optical microscopy method and the 
obtained average particle size ranges from 20-120 µm. While analyzing 
the optimized formulation (LRS-O) it was found that the maximum 
frequency of particles (27.5±0.07 %) was in the range 80-100 µm.  
Surface morphology 
SEM of the optimized PAN-loaded microballoon (LRS-O) showed 
rough surface, spherical shape with internal hollow cavity. No drug 
crystals were found on the surface of microballoons, indicates that the 
drug was homogeneously dispersed within the polymer blend (fig. 5).  
 
Fig. 5: Scanning electron micrographs (a) surface appearance 
(b) cross-sectional view and (c) porous boundary wall of 
formulation LRS-O 
Fourier transform infrared spectroscopy  
Eudragit®L100 gave characteristic bands at 3613, 2950, 1708, 1450, 
1153, 839 and 753 cm-1 which was due to the presence of [O  ̶H]str; 
[C ̶ H]str; [C=O]str; [C  ̶ H]Bend in plane; [C  ̶ O]str; [C ̶ C]str and [C  ̶ H]Rocking. 
Eudragit®RS100 showed the bands at 2951, 1724, 1448, 1238, 1143, 
988, 848 and 752 cm-1which corresponds to [C  ̶ H]str; [C=O]str; [C ̶ 
H]Bend in plane; [C  ̶ N]str; [C ̶ O]str; [C ̶ C]str; [C ̶ H]Rocking and [C  ̶ Cl]str. The 
principle FTIR peaks of pure drug PAN were observed at 2942, 
1588, 1376, 1303, 1040, 983, 838 and 796 cm-1 which was due to [C ̶ 
H]str; [C=N]str; [S=O]str; [C ̶ H]def; [C ̶ F]str; [C ̶ O]str; [C ̶ C]str and [N ̶ 
H]Rocking. While LRS O showed peaks at 3466, 2955, 1724, 1473, 
1438, 1449, 1271, 1144 and 1040 which was due to [O  ̶H]str; [C ̶ H]str; 
[C=O]str; [C=N]str; [S=O]str; [C ̶ H]Bend in plane; [C ̶ N]str; [C ̶ O]str and [C  ̶F]str 
respectively (fig. 6).  
In vitro drug release 
The study for all the formulated PAN-loaded microballoons (LRS 1-8 
and LRS-O) and marketed formulation (LRS-M) were carried out in 
PB pH 6.8 and 7.4 (fig. 7). All the formulations and the marketed 
formulation sustained the PAN release over 12 hrs. This is attributed 
due to Magnesium stearate which lowers the density in turn 
provides buoyancy to the system thus retards and sustains the 
release up to 12 hrs [29]. 
The use of polymer mixture along with plasticizer increases the 
density of the polymer matrix and thus increases the diffusion path 
length, which favors in prolonged drug release characteristics. 
Moreover Eudragit®E100 dissolution occurs above pH 6 and hence 
prolongs the release whereas Eudragit®RS100 is pH independent 
polymer and the ammonium group present favors channel 
formation for the dissolution medium to enter thus initiates 
dissolution and diffusion of drug [30]. 
Kinetics of drug release 
The in vitro drug release data of formulations (LRS-2, O and M) for 
both mediums PB pH 6.8 and 7.4 were fitted in to kinetic models 
such as zero order, first order, Higuchi, and Korsmeyer-Peppas and 
the results obtained was given in table 4. When respective 
correlation coefficients of these formulations in both the mediums 
were compared, the PAN release from formulations LRS-2, O and M 
in PB pH 6.8 follows zero order over a period of 12 hrs, with initial 
burst release in first hour than sustained it for the rest of the period. 
Whereas in PB pH 7.4 the formulations LRS-O and M follows zero 
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order release rate while LRS-2 follows Korsmeyer-Peppas model 
with release exponent ⃰n = 0.1, follows fickian release mechanism 
(diffusion-controlled with ⃰ n ≤ 0.43), thus offers diffusion-
controlled PAN release from microballoons. 
 
 
Fig. 6:FTIR spectra of (a) PAN, (b) Eudragit®L100, (c) 




Fig. 7: Comparative cumulative percentage in vitro drug release 
profiles of Best (B), Optimized (O) and Marketed (M) LRS 
formulations in PB pH 6.8 and 7.4 for 12 h (37±0.5 oC, 300 rpm) 
 
Stability study 
The results of stability study of the optimized formulation carried 
out for a period of six months showed no physical change among 
themselves. The ANOVA table values for F at 5 % level of significance 
for B % and EE % was 16.29 and 15.16 in PB pH 6.8 and 9.08 and 
28.29 in PB pH 7.4.  
DISCUSSION 
The floating buoyant system for the administration of acid labile 
drugs through oral route using acrylic polymers was successfully 
formulated employing 23 factorial designs by emulsion solvent 
diffusion method. The conventional pulsatile release enteric dosage 
forms usually shows a drug release lag period of 5-6 h in large 
intestine affecting the efficacy [31, 32]. Moreover in small intestine 
the higher viscosity of contents may sometimes cause hindrance to 
drug diffusion and degradation by enzymes, so an effective enteric 
coat was recommended for the intestinal delivery [33]. The present 
study clearly demonstrates how effectively concentration of 
polymer mixture could sustain and enhance the gastric retention to 
increase the bioavailability [34]. Since the drug used was highly 
soluble and permeable so in order to retard its release and to 
protect its degradation from acidic environment we have used 
Eudragit®L100 and RS100 in definite proportions.  
In the design Magnesium stearate in higher concentration 5 % w/w 
provides hydrophobicity to the formulation thus reduces the density 
and provides floatability. Also it may inhibit the hydration of the 
polymer matrices and thus sustains the drug release profile of PAN 
from the buoyant systems [35]. Eudragit®L100 in low concentration 
encapsulates the drug and retards its release in stomach as it shows 
pH dependent dissolution in jejunum whereas Eudragit®RS100 in 
low concentration decreases the drug release and increases the 
entrapment efficiency as the pore formed will be less and shows pH 
independent dissolution after swelling in the GIT. In the swollen 
state it is permeable to water and dissolves actives [36]. The 
swelling depends on the relative rate of diffusion of medium through 
pores inside the polymer matrix and on the rate of polymer chain 
relaxation [37]. In order to enhance the solubility of Eudragit®RS100 
in the solvent mixture, plasticizer DBT was used that reduces its 
glass transition temperature. The B % was correlated to the use of 
equal amount of solvents ethanol and dichloromethane for the 
dissolution of polymers, they evaporates forming cavity inside when 
stirred at 40 °C in PVA solution containing sodium citrate buffer. 
Thus both dissolution and disruption of microballoons in acidic 
environment could be prevented that may be advantageous in 
prolonging the GRT. 
Increase in the size was found with increase in the polymer ratios in 
the formulations. This could be attributed due to the increased 
viscosity of the emulsion when cross-linking agent (DBT) was added 
that in turn increases the droplet size when poured in to the PVA 
solution. The porosity or channels on the boundary wall was due to 
the porous nature of the polymer Eudragit®RS100 and also due to 
channeling effect of sodium chloride. The rough appearance of LRS-
O may be attributed to the use of plasticizer (DBT) that results in 
higher cross-linking. In case of LRS-O formulation all characteristic 
bands of PAN appeared with slight variations in wave numbers that 
is due to the higher cross-linking, indicates that there were no 
chemical interactions between the pure drug and the polymers used.  
Passive diffusion of drug from microballoons showed to occur in two 
steps firstly, the leaching out of drug through pores in to the 
polymer matrix, secondly diffusion from matrix in to the dissolution 
medium [38]. As dissolution medium enters the formulation the pH 
sensitive polymer swells, the swollen particles forms closely packed 
network, which hinders further entry of dissolution medium thus 
results in retardation of drug release over 12 h study [39, 40]. The 
optimized LRS-O follows zero order release model, independent of 
the concentration of polymers used whereas LRS-2 follows 
relaxation-controlled mechanism [41]. 
To restrict the number of trials for optimization, RSM was 
successfully used that saves time, more effective and economical 
when compared to the conventional methods [42, 43]. For the 
reliability of the model design dissolution test was performed for 
both, the formulations with predicted optimum polymer 
concentrations and for the additional check point formulation 
covering the entire experimental domain [44]. Design Expert 
software provides the ANOVA provision for the statistical validation 
of polynomials. Subsequently, the feasibility and grid searches were 
performed to locate the composition of optimum formulations [45]. 
Model simplification was carried out by eliminating the non-
significant terms [46]. Statistically significant difference between in 
vitro drug releases of PAN from the formulations was defined as 
⃰p<0.05 [47]. During the stability studies since the calculated value 
for F was found to be less than the tabulated (F Tab = 225), the 
difference was not significant and we conclude that the means do 
not differ among themselves only a slight decrease in buoyancy and 
entrapment efficiency was observed that was insignificant. 
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Table 4: Different drug release models as applied to percentage drug release profiles of LRS-2, O and M formulations in PB pH 6.8 and 7.4 
Code PB Evaluation parameters Zero order  First order Higuchi model Peppas model Best fit model 
LRS-2 pH6.8 r2 0.973 0.970 0.948 0.914  Zero order 
 A 65.20 1.822 52.87 1.805 
B 2.674 0.014 12.19 0.150 
pH7.4 r2 0.938 0.909 0.984 0.991 Korsmeyer-Peppas 
A 69.61 1.846 56.73 1.823 
B 2.561 0.013 12.11 0.152 
LRS-O pH6.8 r2 0.993 0.985 0.976 0.934 Zero order  
A 55.72 1.762 38.60 1.737 
b 3.675 0.020 16.82 0.218 
pH7.4 r2 0.999 0.996 0.972 0.928 Zero order  
A 54.27 1.752 37.55 1.728 
b 3.634 0.020 16.55 0.217 
LRS-M pH6.8 r2 0.994 0.986 0.987 0.947 Zero order  
A 68.85 1.844 56.58 1.827 
b 2.603 0.013 11.97 0.143 
pH7.4 r2 0.998 0.997 0.968 0.922 Zero order  
A 56.68 1.769 40.65 1.747 
b 3.494 0.019 15.89 0.204 
 PB: phosphate buffer; LRS-O: Optimized formulation; LRS-M: Marketed formulation 
 
CONCLUSION 
The study demonstrates the potential of PAN-loaded microballoons 
prepared by emulsion solvent diffusion method employing non-
effervescent technique with 23factorial designs for the intestinal 
delivery. This technique may be advantageous in achieving 
enhanced bioavailability of acid labile drugs for the gastro retentive 
delivery with excellent responses of B %, EE % and CDR12 h % 
following zero order patterns. The Design Expert software used for 
the optimization and validation of formulation design was 
economical and reduces the number of trials. SEM confirms the 
spherical shape with rough surface, porous boundary wall and 
internal hollow cavity moreover the FTIR results showed that there 
were no drug-polymer interactions found. 
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